We look forward to meeting investors at the Swiss Biotech Day 2024, April 22.-23. in Basel. We are very excited to discuss our promising program and how we can bring this to patient faster.
Info
EvlaBio AG is a biotech company, focused on the development of a therapy addressing a high unmet medical need in the cardiorenal space. Specifically, we are addressing Left Ventricular Hypertrophy (LVH) in the setting of chronic kidney disease, which affects millions of patients and for which there are limited treatment options.
- Website
-
www.evlabio.com
Externer Link zu EvlaBio AG
- Branche
- Biotechnologie
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Zurich
- Art
- Privatunternehmen
- Gegründet
- 2022
Orte
-
Primär
Wegbeschreibung
Zurich, CH
Beschäftigte von EvlaBio AG
Updates
-
EvlaBio AG hat dies direkt geteilt
Many thanks Novo Nordisk for selecting EvlaBio as one of the winners for the Golden Ticket 2024 and thank you to BioLabs for the great event and organization.
🎉 Congratulations to Arcneos (Florian T. Merkle), EvlaBio AG (Wenzel von der Heydte and Team), Tissue Dynamics (Yaakov Nahmias, Amir Dagan) and Velakor Biotherapeutics (Kfir Umanski), on winning the Golden Tickets awarded by Novo Nordisk. BioLabs / BioLabs Heidelberg / BioLabs France are delighted to welcome you to our global #community and to see how your therapeutic concepts and your companies will develop, thrive and grow. #ecosystem #startups #entrepreneurship #therapeutics #cardiovascular #diabetis 🙏 We extend our gratitude to the Novo Nordisk team, especially Daniel Timmermann and Itai Kela, PhD, MBA running this Golden Ticket campaign with us. Thanks for coming to our BioLabs European Investor Day in Paris to award the Golden Tickets and appreciate the great innovations the four teams are working on. The European BioLabs teams (Johannes Fruehauf, Johanna Michielin, Ann-Kristin Mueller, Christophe Tallec) are grateful to have you as our partner. Stay tuned to hear more from those promising companies. 🚀 #goldenticket
-
-
Many thanks Novo Nordisk for selecting EvlaBio as one of the winners for the Golden Ticket 2024 and thank you to BioLabs for the great event and organization.
🎉 Congratulations to Arcneos (Florian T. Merkle), EvlaBio AG (Wenzel von der Heydte and Team), Tissue Dynamics (Yaakov Nahmias, Amir Dagan) and Velakor Biotherapeutics (Kfir Umanski), on winning the Golden Tickets awarded by Novo Nordisk. BioLabs / BioLabs Heidelberg / BioLabs France are delighted to welcome you to our global #community and to see how your therapeutic concepts and your companies will develop, thrive and grow. #ecosystem #startups #entrepreneurship #therapeutics #cardiovascular #diabetis 🙏 We extend our gratitude to the Novo Nordisk team, especially Daniel Timmermann and Itai Kela, PhD, MBA running this Golden Ticket campaign with us. Thanks for coming to our BioLabs European Investor Day in Paris to award the Golden Tickets and appreciate the great innovations the four teams are working on. The European BioLabs teams (Johannes Fruehauf, Johanna Michielin, Ann-Kristin Mueller, Christophe Tallec) are grateful to have you as our partner. Stay tuned to hear more from those promising companies. 🚀 #goldenticket
-